How has Avalo Therapeutics's research and development expense changed year-over-year?

Avalo Therapeutics's research and development expense increased by 54.0% year-over-year, from $9.12M to $14.05M.

What is the long-term trend for Avalo Therapeutics's research and development expense?

Over 4 years (2021 to 2025), Avalo Therapeutics's research and development expense has grown at a -4.3% compound annual growth rate (CAGR), from $59.84M to $50.09M.

Avalo Therapeutics AVTX Research and development expense

Research and development expense at other companies

Eli LillyLLY

——

AbbVieABBV

——

AnaptysBio, Inc.ANAB

——

Immunovant, Inc.IMVT

——

Other financials

Income statement

See full

Revenue$59.0K-69.3%

Gross profit$963.0K+8,855%

Operating income-$20.9M-42.5%

Net income-$19.6M-49.3%

EPS (diluted)-$0.98+21.6%

Balance sheet

See full

Cash & equivalents$25.3M-79.8%

Total debt$328.0K-59.1%

Total equity$68.3M-44.3%

Total assets$99.9M-27.9%

Cash flow

See full

Operating cash flow-$17.7M-87.1%

CapEx-—

Free cash flow-$15.0M-444%

Valuation

See full

Market cap$946.18M+1,783%

Enterprise value$921.19M-1,342%

P/S1,892.4×+1,852×

Profitability

See full

Gross margin182%+176pp

Operating margin-15,536.1%-17,275pp

Net margin-7,965.8%-10,750pp

FCF margin-11,123.8%-13,374pp

Returns & leverage

See full

Return on equity-88.8%—

Debt / equity0×0.0×

Current ratio7.7×-14.9×

Where this comes from

Reported directly by Avalo Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.

The official record: Avalo Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Avalo Therapeutics's research and development expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Avalo Therapeutics's research and development expense?: Avalo Therapeutics (AVTX) reported research and development expense of $14.05M in Q1 2026.
How has Avalo Therapeutics's research and development expense changed year-over-year?: Avalo Therapeutics's research and development expense increased by 54.0% year-over-year, from $9.12M to $14.05M.
What is the long-term trend for Avalo Therapeutics's research and development expense?: Over 4 years (2021 to 2025), Avalo Therapeutics's research and development expense has grown at a -4.3% compound annual growth rate (CAGR), from $59.84M to $50.09M.